Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells 16,167 Shares of Stock

Key Points

• SVP Adam Veness sold 16,167 Dianthus Therapeutics shares at an average price of $110.38, generating approximately $1.78 million. The transaction reduced his remaining stake by 80.84% to 3,833 shares.
• DNTH shares fell 3.0% to $108.49, while the company reported a quarterly loss of $0.90 per share, missing estimates by $0.05. Revenue of $0.76 million exceeded the $0.30 million consensus forecast.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $124.27; HC Wainwright recently raised its target to $158. Institutional investors own 47.53% of the company.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) SVP Adam Veness sold 16,167 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $110.38, for a total value of $1,784,513.46. Following the completion of the transaction, the senior vice president owned 3,833 shares in the company, valued at $423,086.54. The trade was a 80.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Get Dianthus Therapeutics SMS alerts:

Sign Up

Dianthus Therapeutics Trading Down 3.0%

Shares of DNTH stock traded down $3.31 during trading on Tuesday, hitting $108.49. The company's stock had a trading volume of 777,875 shares, compared to its average volume of 972,407. The company has a market cap of $5.93 billion, a PE ratio of -26.14 and a beta of 1.22. The business has a fifty day moving average of $95.17 and a 200-day moving average of $81.36. Dianthus Therapeutics, Inc. has a 52 week low of $19.00 and a 52 week high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, research analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $27,000. First Horizon Corp bought a new stake in shares of Dianthus Therapeutics in the first quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $40,000. Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics during the 3rd quarter valued at approximately $64,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after buying an additional 3,317 shares during the period. Institutional investors own 47.53% of the company's stock.

Analyst Ratings Changes

DNTH has been the topic of a number of research analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. HC Wainwright raised their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Wolfe Research reaffirmed an "outperform" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Guggenheim reiterated a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, TD Cowen reiterated a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $124.27.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source